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Background: The autophagic vacuolar myopathies (AVM) are a group of inherited myopathies defined by the
presence of autophagic vacuoles in pathological muscle specimens. AVM can be categorized into three groups:
acid maltase deficiency, myopathies characterized by autophagic vacuoles with unique sarcolemmal features, and
rimmed vacuolar myopathies (RVM). While the pathogeneses of these conditions are still being elucidated, some
drugs (e.g., chloroquine, its analog, hydroxychloroquine, and colchicine) can also cause AVM. Minocycline is a
disease-modifying anti-rheumatic drug that may be used in the treatment of rheumatoid arthritis (RA). Here, we
describe the first case of minocycline-associated AVM with rimmed vacuole formation.
Case presentation: A 75-year-old woman suffering from RA has been continuously treated with minocycline (200
mg/day) for the past 7 years. During this time, she developed a myopathy that predominantly affected her lower
limbs. Histological studies of biopsied muscle revealed scattered atrophic myofibers with rimmed vacuoles that
contained pigment granules. Histochemical staining revealed that the pigment comprised both iron and melanin,
which is consistent with type II minocycline-induced cutaneous pigmentation. Under electron microscopy,
autophagic vacuoles were consistently observed in association with numerous collections of pigment granules.
Conclusions: This is the first report of minocycline-induced pigmentation in skeletal muscle. The strong association
between autophagic vacuoles and the accumulation of minocycline-induced pigments suggest that long-term
minocycline treatment induced pigment accumulation, leading to elevation of autophagic activity and RVM. It
might also be possible that minocycline directly activated autophagy, as the observed pigments are known to form
complexes containing minocycline and/or its metabolites. As long-term minocycline treatment is expected to be
used more widely in the future, we must draw attention to this adverse effect.
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Rheumatoid arthritisBackground
Autophagy, which is a lysosomal degradation pathway
that is essential for cell survival [1], plays a key role in
the pathogenesis of several inherited myopathies; these
include autophagic vacuolar myopathies (AVM) [2] as
well as the drug-induced AVM caused by chloroquine,
hydroxychloroquine and colchicine [3,4]. Both inhibition
and activation of autophagy can lead to the appearance
of autophagic vacuoles in pathological muscle specimens
[1,2]. In addition to the best characterized AVM, Pompe
disease, two other categories of AVM have recently* Correspondence: keizo_sugaya@member.metro.tokyo.jp
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reproduction in any medium, provided the oremerged. One is Danon disease and its related disorders,
which are characterized by autophagic vacuoles with
unique sarcolemmal features [5]. The other is typified by
the presence of rimmed vacuoles (vacuoles within myofi-
bers that are lined with blue granular material following
hematoxylin-eosin staining or with red material follow-
ing modified Gomori trichrome staining); electron mi-
croscopy has revealed that these are actually clusters of
autophagic vacuoles [5].
Minocycline is a semi-synthetic derivative of tetracyc-
line that functions as a broad-spectrum antimicrobial
agent and has proven to be a moderately effective
disease-modifying anti-rheumatic drug in the treatment
of rheumatoid arthritis (RA) [6]. The drug is generally
well tolerated, but long-term use of minocycline (100 toLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Skin hyperpigmentation of the patient. Blue-black
pigmentation related to minocycline therapy was observed on the
distal parts of the patient’s legs.
Bokuda et al. BMC Neurology 2012, 12:140 Page 2 of 6
http://www.biomedcentral.com/1471-2377/12/140200 mg/day), especially in the management of acne vul-
garis or RA, can be associated with a number of side
effects. The most common adverse drug reactions are
photosensitivity and esophagitis, while the rarer adverse
events include severe allergic reactions, such as Stevens-
Johnson syndrome, systemic lupus erythematosus, serum
sickness, autoimmune hepatitis, vasculitis and dermato-
myositis [7,8]. Long-term use of minocycline can also
cause pigmentation, which is a well-recognized adverse
effect that affects the skin and other organs [9]. To our
knowledge, this is the first report of rimmed vacuolar
myopathy (RVM) associated with long-term minocycline
treatment, wherein cluster of autophagic vacuoles are




A 75-year-old woman was admitted to our hospital due
to a 2-year history of gradually progressive gait disturb-
ance. She had suffered from RA since the age of 25. Be-
cause of an exacerbation of this disease, she started
taking prednisolone (5 mg/day) and sulfasalazine at 67
years, and had been continuously treated with minocy-
cline (200 mg/day) since the age of 68. She noticed a
gradual increase in blue-black skin pigmentation on
both legs at 72 years. Thereafter, she began to have diffi-
culty walking, and would frequently catch the tip of her
foot on the ground. No exposure to other drugs known
to cause pigmentary changes was recorded.
Examination of the patient revealed blue-black pig-
mentation related to minocycline therapy on the distal
parts of the legs (Figure 1). The muscle strength was
normal in the upper limbs and trunk, but she was un-
able to perform toe- or heel-walking. There was mild
symmetrical weakness and atrophy in the lower limb
muscles, but no wide-based gait. Strength testing was
performed using Medical Research Council grades, and
the results were as follows: hip flexion 4+/5, hip exten-
sion 4+/5, knee extension 4/5, knee flexion 4-/5, ankle
dorsiflexion 4-/5, and ankle plantar flexion 4-/5. The
tendon reflexes were normal except for the absence of
ankle jerks. A stocking distribution decrease in appreci-
ation of superficial pain was identified in both legs.
Vibration sensation was decreased in the toes and
ankles. Laboratory tests, including creatine kinase levels,
were normal except for the tests related to RA. Chest
roentgenogram and electrocardiogram showed no ab-
normalities. A nerve conduction study demonstrated no
detectable abnormalities except for low amplitude in the
bilateral sural nerve action potentials. Needle electro-
myography showed low amplitude and short duration
motor-unit potentials with early recruitment in the
quadriceps femoris, biceps femoris and tibialis anteriormuscles. No abnormal spontaneous activity was seen in
any of the muscles. Skeletal muscle CT revealed diffuse
muscular atrophy of the lower extremities. Because the
patient was suspected of having myopathy and sensory
neuropathy, peroneus muscle and sural nerve biopsies
were performed after informed consent was obtained.
Histology
The biopsied specimens were snap-frozen in isopentane-
liquid nitrogen, and cryosections were stained with a
standard battery of histological and histochemical reac-
tions. Paraffin-embedded tissue sections were also
stained with Prussian blue stain (for iron), Masson
Fontana preparation (for melanin) and hydrogen perox-
ide melanin bleach. Histopathological studies of the
biopsied muscle revealed modest variability in myofiber
diameter with scattered angular atrophic fibers
(Figure 2A). There were a considerable number of atro-
phic fibers with rimmed vacuoles (Figure 2B), and multiple
collections of granular pigment-containing histiocytes in
Figure 2 Light microscopy of muscle biopsy. A: Modest variability in myofiber diameter with scattered angular atrophic fibers (hematoxylin-
eosin staining). Rimmed vacuole is shown at higher magnification (insert). B: Atrophic fibers with rimmed vacuoles (arrow, modified Gomori
trichrome staining). C: Granular pigment-containing histiocytes in endomysial areas and rimmed vacuoles showing high acid phosphatase activity
(compared to the rimmed vacuole on modified Gomori trichrome staining [insert]). D: NADH-tetrazolium reductase reaction shows dark-brown
depositions in myofibers and vacuoles (compared to the rimmed vacuole on modified Gomori trichrome staining [insert]). E: Histiocytic pigment
stained bright blue with Prussian blue. F: Histiocytic pigment stained black on a Masson Fontana preparation.
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granules and rimmed vacuoles showed high acid phos-
phatase activity (Figure 2C). The pigmentation was mainly
found outside the myofibers, but the NADH-tetrazolium
reductase reaction readily identified dark-brown deposi-
tions in some fibers. Almost all of the rimmed vacuoles
contained granular depositions (Figure 2D). No necrotic
or regenerating fibers were present. There was no inflam-
matory infiltrate, except for histiocytes containing pigment
that stained bright blue with the Prussian blue (Figure 2E).
This histiocytic pigment stained black on a Masson
Fontana preparation (Figure 2F), bleached in response to
potassium permanganate, and showed no fluoresce under
ultraviolet light, indicating that it was composed of iron
and melanin.
Electron microscopy was performed on glutaraldehyde-
fixed tissue using a standard electron microscopic proces-
sing protocol and a transmission electron microscope.
Electron microscopy revealed that the pigment granules
were localized in the cytoplasm of histiocytes, in the
spaces between myofibers, and adjacent to small blood
vessels (Figure 3A). In the myofibers, the granules were
localized in the subsarcolemmal cytoplasm, either indi-
vidually (Figure 3B) or in clusters (Figure 3C). Remark-
ably, autophagic vacuoles were consistently observed in
association with many of the granular pigment clusters(Figure 3D, E). Two distinct morphological patterns were
evident among the granules found in myofibers: irregu-
larly shaped, highly electron-dense granules, and
membrane-bound vesicles of differing electron density
with distinct internal structures, often associated with
small lipid droplets.
In addition to the standard battery of histological
stains, the sural nerve biopsy specimen was embedded
in epoxy resin and examined by light and electron
microscopy. Light microscopy of the sural nerve showed
a reduction in the number of large diameter myelinated
fibers, but no other specific features (Figure 3F). How-
ever, Prussian blue and Masson Fontana staining
revealed perivascular deposits of iron and melanin in the
epineurial blood vessels. Electron microscopy revealed a
few highly electron-dense granules in the cytoplasm of
Schwann cells, where the myelin sheath was disrupted
(Figure 3G).
Discussion
The incidences of minocycline-induced cutaneous pig-
mentation have been reported in up to 41% of patients
with RA who take minocycline [10]. Histochemical
staining for pigmented substances (e.g., iron, melanin)
has shown that minocycline-induced cutaneous pigmen-
tation can be classified into three or four distinct types
Figure 3 Electron microscopy of muscle biopsy and nerve pathology. A: Pigment granules in the cytoplasm of histiocytes. B: Isolated
pigment granule in the subsarcolemmal cytoplasm. C: Pigment granules form a small cluster in a myofiber. D, E: Autophagic vacuoles (pink
arrowhead) in association with numerous pigment granule clusters (blue arrowhead). F: Light microscopy of the sural nerve specimen shows a
reduction in the number of large-diameter myelinated fibers. G: Electron microscopy of the sural nerve specimen shows electron-dense granules
in the cytoplasm of a Schwann cell, where the myelin sheath is disrupted.
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biopsied muscle demonstrated that the pigments
comprised iron and melanin, which is consistent with
type II minocycline-induced cutaneous pigmentation
[11]. Iron deposition in skeletal muscle has rarely been
described in some disorders, including idiopathic
hemochromatosis, transfusion induced hemosiderosis,
diabetic neuropathy, Waldenstrom’s macroglobulinemia,
and AIDS patients [12-14]. Laboratory investigations of
our patient showed no evidence of these conditions. No
previous study has reported melanin deposition in
human skeletal muscle, except for cases of melanoma
invasion. Here, we report the first identification of
minocycline-induced pigmentation (comprising iron and
melanin) in skeletal muscle.
The sural nerve biopsy demonstrated the features of a
chronic axonal neuropathy, with minimal pigment
observed in the cytoplasm of Schwann cells. Only a few
cases of minocycline-associated sensory neuropathy have
been reported, and axonal-type sensory neuropathy is a
common complication in RA [15]. Thus, it is unclear
whether or not the sensory neuropathy observed in our
patient is related to minocycline therapy.
Tissue pigmentation due to minocycline treatment is
not usually harmful [9]. However, the striking finding in
the biopsied muscle from our patient is the presence of
rimmed vacuoles that had acid phosphatase-positive
autophagic activity and contained numerous pigmentedgranules in various forms. The strong association be-
tween autophagic vacuoles and the accumulation of
minocycline-induced pigments is evident. The rimmed
vacuoles were positive for p62/SQSTM1 (p62) immu-
nostaining (Figure 4A), which has been reported as a
diagnostic marker for drug-induced AVM [16]. In distal
myopathy with rimmed vacuoles (DMRV), activation of
autophagy is thought to occur via the accumulation of
unfolded/misfolded proteins [2]. No filamentous inclu-
sion (representing the accumulation of unfolded/mis-
folded proteins) was seen on electron microscopy of
samples from our patient. There was also no immunos-
taining inclusion seen under light microscopy of samples
immunostained with an antibody against TAR-DNA
binding protein-43 (TDP-43) (Figure 4B). TDP-43-
positive inclusions are thought to be a common end-
point of muscle degeneration among the myopathies
associated with rimmed vacuoles, such as DMRV, inclu-
sion body myositis and oculopharyngeal muscular dys-
trophy [17]. All of these conditions have been associated
with the presence of filamentous inclusions in myofibers.
Thus, our findings suggest that long-term minocycline
treatment might cause RVM by activating autophagy
through the accumulation of minocycline-induced pig-
ments. Although no previous report has shown minocy-
cline therapy directly linked to autophagy in human
disease, two recent studies using different in vitro cul-
ture systems found that minocycline induced autophagy
Figure 4 Immunohistochemistry of muscle biopsy. Immunohistochemistry was performed on serial paraffin sections. Sections were immersed
in citrate buffer, heated in a microwave for antigen retrieval, and immunostained with antibodies against p62/SQSTM1 (1:2000; Progen) (A) and
TAR-DNA binding protein-43 (1:500; Protein Tech Group) (B) according to standard procedures. The immunostaining was visualized with
diaminobenzidine tetrahydrochloride and counterstained with methylene blue. Arrow indicates p62 immuno-positive aggregates within rimmed
vacuoles. Some nuclei are normally immunostained with TDP-43.
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glioma cells and epidermoid cancer cells [18,19]. In
addition, minocycline-induced pigments are known to
form complexes containing minocycline and/or its meta-
bolites [20,21], suggesting that minocycline could dir-
ectly activate autophagy.
One year after the cessation of minocycline therapy,
our patient exhibited no worsening of gait disturbance.
There was little improvement in muscle weakness, how-
ever, perhaps because she had taken minocycline for an
extremely long duration even after the appearance of
skin pigmentation. This is an unusual condition. How-
ever, long-term minocycline treatment may be used
more widely in the future, as on-going clinical trials are
assessing the therapeutic use of minocycline as an anti-
inflammatory agent in a broad range of disorders. Thus,
we must draw attention to this adverse effect because its
insidious onset, slowly progressive course, and lack of
creatine kinase elevation could complicate its prompt
identification in patients.
Chloroquine and hydroxychloroquine are anti-malarial
drugs that are also used to treat RA and systemic lupus
erythematosus. Hydroxychloroquine is used much more
frequently than chloroquine, as the latter is more likely
to cause irreversible retinal damage. Long-term hydroxy-
chloroquine treatment rarely causes myopathy and sen-
sory neuropathy; the former typically manifests with an
insidious onset and normal-to-mildly-elevated creatine
kinase levels, and muscle biopsy consistently reveals
curvilinear bodies and muscle fiber atrophy with vacu-
olar changes [3,22]. After the therapy is discontinued,
the resolution of symptoms is slow and may be incom-
plete. In rare cases, long-term hydroxychloroquine treat-
ment can also cause skin pigmentation [23]. In all
reported cases, the main histological feature of
hydroxychloroquine-induced pigmentation was the pres-
ence of iron and melanin deposits in the dermis [23].
These features are very similar to those observed in ourpatient, who had never taken the anti-malarial drugs,
suggesting that there may be a common pathogenic
mechanism underlying these conditions. Hydroxychloro-
quine myopathy is usually of mild to moderate severity,
but a few case of severe hydroxychloroquine myopathy,
involving respiratory muscles and/or cardiac myocytes,
have been reported [24,25]. However, our patient did not
have any symptoms related to respiratory or cardiac dys-
function. Chloroquine and hydroxychloroquine accumu-
late within lysosomes and are thought to block
autophagy by elevating intralysosomal pH and inhibiting
lysosomal enzymes [26,27]. However, the exact mechan-
ism underlying myocyte toxicity is unclear. In the future,
it will be particularly interesting to examine whether
iron and melanin are deposited in the muscles of hydro-
xychloroquine myopathy patients.Conclusions
Minocycline has proven to be an effective disease-
modifying anti-rheumatic drug. However, we herein re-
port for the first time that long-term minocycline treat-
ment may cause RVM via the accumulation of
minocycline-induced pigmentation in skeletal muscle.
The clinical features of minocycline-associated RVM are
very similar to those observed in hydroxychloroquine
myopathy, suggesting that there may be a common
pathogenic mechanism underlying these conditions. As
long-term minocycline treatment may be used more
widely in the future, we must draw attention to this ad-
verse effect.Consent
Written informed consent was obtained from the patient
for publication of this case report. A copy of the written
consent is available for review by the Editor-In-Chief of
this journal.
Bokuda et al. BMC Neurology 2012, 12:140 Page 6 of 6
http://www.biomedcentral.com/1471-2377/12/140Abbreviations
AVM: Autophagic vacuolar myopathy; RVM: Rimmed vacuolar myopathy;
RA: Rheumatoid arthritis; p62: p62/SQSTM1; TDP-43: TAR-DNA binding
protein-43; DMRV: Distal myopathy with rimmed vacuoles.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
Study concept and design: KS. Acquisition of the data: KB, ST, KS. Analysis
and interpretation: KB, KS, KM, SM, TK. Wrote the paper: KB, KS, SM. All
authors read and approved the final manuscript.
Acknowledgements
This study was funded by the Tokyo Metropolitan Government.
Author details
1Department of Neurology, Tokyo Metropolitan Neurological Hospital, 2-6-1
Musashidai, Fuchu, Tokyo 183-0042, Japan. 2Department of Laboratory
Medicine and Pathology, Tokyo Metropolitan Neurological Hospital, 2-6-1
Musashidai, Fuchu, Tokyo 183-0042, Japan.
Received: 8 September 2012 Accepted: 20 November 2012
Published: 21 November 2012
References
1. Levine B, Kroemer G: Autophagy in the pathogenesis of disease. Cell 2008,
132:27–42.
2. Nishino I: Autophagic vacuolar myopathy. Semin Pediatr Neurol 2006,
13:90–95.
3. Casado E, Gratacos J, Tolosa C, Martinez JM, Ojanguren I, Ariza A, Real J,
Sanjuán A, Larrosa M: Antimalarial myopathy: an underdiagnosed
complication? Prospective longitudinal study of 119 patients. Ann Rheum
Dis 2006, 65:385–390.
4. Kuncl RW, Duncan G, Watson D, Alderson K, Rogawski MA, Peper M:
Colchicine myopathy and neuropathy. N Engl J Med 1987, 316:1562–1568.
5. Nishino I: Eludication of pathomechanism of and development of
therapy for autophagic vacuolar myopathy. Rinsho Shinkeigaku 2010,
50:1–6.
6. Smith CJ, Sayles H, Mikuls TR, Michaud K: Minocycline and doxycycline
therapy in community patients with rheumatoid arthritis: prescribing
patterns, patient-level determinants of use, and patient-reported side
effects. Arthritis Res Ther 2011, 13:R168.
7. Joshi H, Chhikara V, Arya K, Pathak R: Some undesirable effects reported in
past five years related to minocycline therapy: a review. Ann Biol Res
2010, 1:64–71.
8. Geddes MR, Sinnreich M, Chalk C: Minocycline-induced dermatomyositis.
Muscle Nerve 2010, 41:547–549.
9. Eisen D, Hakim MD: Minocycline-induced pigmentation. Incidence,
prevention and management. Drug Saf 1998, 18:431–440.
10. Roberts G, Capell HA: The frequency and distribution of minocycline
induced hyperpigmentation in a rheumatoid arthritis population.
J Rheumatol 2006, 33:1254–1257.
11. Mouton RW, Jordaan HF, Schneider JW: A new type of minocycline-
induced cutaneous hyperpigmentation. Clin Exp Dermatol 2004, 29:8–14.
12. Griggs RC, Markesbery WR, Bauman AW, Callerame ML: Perivascular
hemosiderin deposition in muscle in Waldenstrom’s macroglobulinemia.
J Neurol Sci 1975, 25:153–163.
13. Gherardi RK, Mhiri C, Baudrimont M, Roullet E, Berry JP, Poirier J: Iron
pigment deposits, small vessel vasculitis, and erythrophagocytosis in the
muscle of human immunodeficiency virus-infected patients. Hum Pathol
1991, 22:1187–1194.
14. Davis DG, Markesbery WR: Perivascular siderophages in skeletal muscle
from a patient with diabetic neuropathy. Acta Neuropathol 1992,
84:216–220.
15. Agarwal V, Singh WR, Chauhan S, Tahlan A, Ahuja CK, Goel D, Pal L: A
clinical, electrophysiological, and pathological study of neuropathy in
rheumatoid arthritis. Clin Rheumatol 2008, 27:841–844.
16. Lee HS, Daniels BH, Salas E, Bollen AW, Debnath J, Margeta M: Clinical
utility of LC3 and p62 immunohistochemistry in diagnosis of drug-induced autophagic vacuolar myopathies: a case–control study. PLoS
One 2012, 7:e36221.
17. Küsters B, van Hoeve BJ, Schelhaas HJ, Ter Laak H, van Engelen BG,
Lammens M: TDP-43 accumulation is common in myopathies with
rimmed vacuoles. Acta Neuropathol 2009, 117:209–211.
18. Liu WT, Lin CH, Hsiao M, Gean PW: Minocycline inhibits the growth of
glioma by inducing autophagy. Autophagy 2011, 7:166–175.
19. Du B, Zhang Y, Tang Y, Wang P: Minocycline attenuates ototoxicity and
enhances antitumor activity of cisplatin treatment in vitro. Otolaryngol
Head Neck Surg 2011, 144:719–725.
20. Okada N, Moriya K, Nishida K, Kitano Y, Kobayashi T, Nishimura H, Aoyama
M, Yoshikawa K: Skin pigmentation associated with minocycline therapy.
Br J Dermatol 1989, 121:247–254.
21. Nathaniel ST, Daniel M, Sook-Bin W: Oral mucosal pigmentation secondary
to minocycline therapy: report of two cases and a review of the
literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004,
97:718–725.
22. Stein M, Bell MJ, Ang LC: Hydroxychloroquine neuromyotoxicity.
J Rheumatol 2000, 27:2927–2931.
23. Puri PK, Lountzis NI, Tyler W, Ferringer T: Hydroxychloroquine-induced
hyperpigmentation: the staining pattern. J Cutan Pathol 2008,
35:1134–1137.
24. Siddiqui AK, Huberfeld SI, Weidenheim KM, Einberg KR, Efferen LS:
Hydroxychloroquine-induced toxic myopathy causing respiratory failure.
Chest 2007, 131:588–590.
25. Abdel-Hamid H, Oddis CV, Lacomis D: Severe hydroxychloroquine
myopathy. Muscle Nerve 2008, 38:1206–1210.
26. de Duve C, de Barsy T, Poole B, Trouet A, Tulkens P, Van Hoof F:
Commentary: lysosomotropic agents. Biochem Pharmacol 1974,
23:2495–2531.
27. Stauber WT, Hedge AM, Trout JJ, Schottelius BA: Inhibition of lysosomal
function in red and white skeletal muscles by chloroquine. Exp Neurol
1981, 71:295–306.
doi:10.1186/1471-2377-12-140
Cite this article as: Bokuda et al.: Minocycline-associated rimmed
vacuolar myopathy in a patient with rheumatoid arthritis. BMC Neurology
2012 12:140.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
